Jon Congleton
Chief Executive Officer, Director at Mineralys Therapeutics, Inc. (MLYS)
Jon Congleton has filed 20 insider reports with the SEC since June 2024, as chief Executive Officer and director at Mineralys Therapeutics, Inc. (MLYS) and director at Immunic, Inc. (IMUX). In the last 12 months Jon Congleton sold $16.2M of stock on the open market. In the latest filing, on October 2, 2026, Jon Congleton sold 75,000 shares of Mineralys Therapeutics, Inc. (MLYS) for $1.91M at an average of $25.46.
- Filings
- 20
- Companies
- 2
- Bought on market
- None
- Sold on market
- $19.3M
Companies where Jon Congleton is an insider
| Company | Role | Shares held | Bought | Sold | Last filing |
|---|---|---|---|---|---|
| MLYS Mineralys Therapeutics, Inc. | Chief Executive Officer, Director | 528,621 | $19.3M | Oct 2, 2026 | |
| IMUX Immunic, Inc. | Director | Jul 7, 2026 |
Shares held: common shares owned directly after the latest filing that states it.
Every filing
- Sep 30, 2026-$1.91MMLYSChief Executive Officer Congleton Jon sold $1,909,665 worth of shares (75,000 units at $25.46) as part of a pre-agreed trading plan, decreasing direct ownership by 12% to 528,621 unitsForm 4Open-market sale10b5-1 plan
- Jul 13, 2026-$291KMLYSChief Executive Officer Congleton Jon sold $291,441 worth of shares (10,700 units at $27.24) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 603,621 unitsForm 4Open-market sale10b5-1 plan
- Jul 5, 2026IMUXSEC Form 4 filed by Director Congleton JonForm 4Grant or award
- Jun 30, 2026-$1.96MMLYSChief Executive Officer Congleton Jon sold $1,960,601 worth of shares (75,000 units at $26.14) as part of a pre-agreed trading plan, decreasing direct ownership by 11% to 614,321 unitsForm 4Open-market sale10b5-1 plan
- Jun 29, 2026IMUXSEC Form 4 filed by Director Congleton JonForm 4Grant or award
- Apr 13, 2026-$422KMLYSSEC Form 4 filed by Congleton JonForm 4Open-market sale10b5-1 plan
- Mar 31, 2026-$1.97MMLYSSEC Form 4 filed by Congleton JonForm 4Open-market sale10b5-1 plan
- Feb 19, 2026MLYSChief Executive Officer Congleton Jon was granted 140,900 shares, increasing direct ownership by 22% to 780,051 unitsForm 4Grant or award
- Jan 12, 2026-$530KMLYSChief Executive Officer Congleton Jon sold $529,640 worth of shares (16,236 units at $32.62), decreasing direct ownership by 2% to 639,151 unitsForm 4Open-market sale10b5-1 plan
- Nov 21, 2025MLYSChief Executive Officer Congleton Jon exercised 24,082 shares at a strike of $0.54, increasing direct ownership by 4% to 655,387 unitsForm 4Exercise or conversion of a derivative
- Nov 11, 2025-$9.09MMLYSChief Executive Officer Congleton Jon sold $9,088,499 worth of shares (200,000 units at $45.44), decreasing direct ownership by 24% to 631,305 unitsForm 4Open-market sale
- Oct 13, 2025-$644KMLYSChief Executive Officer Congleton Jon sold $644,327 worth of shares (15,100 units at $42.67), decreasing direct ownership by 2% to 831,305 unitsForm 4Open-market sale10b5-1 plan
- Jul 11, 2025-$230KMLYSChief Executive Officer Congleton Jon sold $230,431 worth of shares (15,884 units at $14.51), decreasing direct ownership by 2% to 846,405 unitsForm 4Open-market sale10b5-1 plan
- Apr 11, 2025-$187KMLYSChief Executive Officer Congleton Jon sold $186,803 worth of shares (15,319 units at $12.19), decreasing direct ownership by 2% to 862,289 unitsForm 4Open-market sale10b5-1 plan
- Feb 13, 2025MLYSSEC Form 4 filed by Chief Executive Officer Congleton JonForm 4Grant or award
- Jan 13, 2025-$166KMLYSChief Executive Officer Congleton Jon sold $166,082 worth of shares (18,333 units at $9.06), decreasing direct ownership by 2% to 877,608 unitsForm 4Open-market sale10b5-1 plan
- Oct 11, 2024-$206KMLYSChief Executive Officer Congleton Jon sold $206,433 worth of shares (15,271 units at $13.52), decreasing direct ownership by 2% to 895,941 unitsForm 4Open-market sale10b5-1 plan
- Jul 11, 2024-$210KMLYSChief Executive Officer Congleton Jon sold $210,075 worth of shares (15,746 units at $13.34), decreasing direct ownership by 2% to 911,212 unitsForm 4Open-market sale10b5-1 plan
- Jun 20, 2024-$592KMLYSChief Executive Officer Congleton Jon sold $592,022 worth of shares (49,313 units at $12.01), decreasing direct ownership by 5% to 926,958 unitsForm 4Open-market sale10b5-1 plan
- Jun 14, 2024-$924KMLYSChief Executive Officer Congleton Jon sold $924,203 worth of shares (72,797 units at $12.70), decreasing direct ownership by 7% to 976,271 unitsForm 4Open-market sale10b5-1 plan
Other insiders at the same companies
- Brian Taylor SlingsbyMLYS
- Eric WarrenMLYS
- Robert Thorvald NagelIMUX
- Bvf Partners L P/ilIMUX
- Daphne KarydasMLYS
- James J. Ferguson IIIMLYS
- David Malcom RodmanMLYS
- Elena RidloffIMUX
- Simona SkerjanecIMUX
- Richard Alan RudickIMUX
- Barclay A PhillipsIMUX
- Joerg NeermannIMUX
- Tamar D HowsonIMUX
- Glenn WhaleyIMUX
- Jason TardioIMUX
- Daniel VittIMUX
Questions about Jon Congleton
- What is Jon Congleton's role at Mineralys Therapeutics, Inc.?
- Jon Congleton reports to the SEC as chief Executive Officer and director at Mineralys Therapeutics, Inc. (MLYS), according to the latest filing on October 2, 2026. Jon Congleton has also filed as director at Immunic, Inc. (IMUX).
- How many shares does Jon Congleton own?
- After the latest filing that states it, Jon Congleton directly owned 528,621 shares of Mineralys Therapeutics, Inc. (MLYS). Shares held through trusts, funds or family members are reported separately and are not counted here.
- Has Jon Congleton bought or sold stock recently?
- The most recent open-market sale was on September 30, 2026: sold 75,000 shares of Mineralys Therapeutics, Inc. (MLYS) for $1.91M at an average of $25.46.
- How do I get alerts when Jon Congleton files?
- Follow Jon Congleton on Quantisnow and you get an email, and a phone notification on Plus, within minutes of each new Form 4 or Form 5. Jon Congleton filed 1 time in the last 90 days.
From SEC Forms 4 and 5 filed by Jon Congleton (SEC CIK 0001644975). Totals count each trade once, skipping amendments whose original is on file, from Jun 14, 2024 on. View on SEC EDGAR